199 related articles for article (PubMed ID: 26796853)
1. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
6. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
9. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
[TBL] [Abstract][Full Text] [Related]
10. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
12. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancer.
Geng X; Pu W; Tan Y; Lu Z; Wang A; Tan L; Chen S; Guo S; Wang J; Chen X
Oncotarget; 2017 Jan; 8(4):6845-6856. PubMed ID: 28036263
[TBL] [Abstract][Full Text] [Related]
14. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
16. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
17. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
18. Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review.
Li Y; Lu DG; Ma YM; Liu H
Oncotarget; 2017 Jan; 8(4):5814-5822. PubMed ID: 28008143
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
20. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]